Investigating the effectiveness of oral tablet based on the Cuscuta epithymum on endometrioma
Phase 2
Recruiting
- Conditions
- Endometrioma.Malignant neoplasm of endometriumC54.1
- Registration Number
- IRCT20220108053669N4
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 68
Inclusion Criteria
Endometriosis with pelvic pain and ovarian cyst over 2 cm
Absence of Müllerian fibrosis adenomyosis and myoma
Not taking medication such as painkillers
Consent
Exclusion Criteria
Patient dissatisfaction
Occurrence of pregnancy
Drug complication
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The effect of drugs on patients pain. Timepoint: Monthly since intervention, two months. Method of measurement: VAS(Visual Analogue Scale).
- Secondary Outcome Measures
Name Time Method Drug effect on ovarian cyst size of patient. Timepoint: Two month since the beginning of intervention. Method of measurement: sonography.;Drug effect on the quality of life of patients. Timepoint: Monthly since intervention, two month. Method of measurement: EHP-30 Questionnaire.;Drug effect on the amount of painkillers usage in patients. Timepoint: Monthly since intervention, two month. Method of measurement: asking from patients.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of Cuscuta epithymum may influence endometrioma progression and pelvic pain?
How does Cuscuta epithymum tablet compare to standard hormonal therapies in managing endometrioma symptoms and cyst size?
Are there specific biomarkers associated with endometrioma that could predict response to Cuscuta epithymum treatment?
What are the potential adverse events of Cuscuta epithymum-based therapy in endometrioma patients and how are they managed?
What are the current combination therapies or competitor drugs for endometrioma treatment alongside Cuscuta epithymum research?